Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

Open access
Granier, Clemence, De Guillebon, Eleonore, Blanc, Charlotte, Roussel, Helene, Badoual, Cecile, Colin, Elia, Saldmann, Antonin, Gey, Alain, Oudard, Stephane, Tartour, Eric·2017·ESMO Open

Abstract

The large family of costimulatory molecules plays a crucial role in regulation of the immune response.These molecules modulate TCR signalling via phosphorylation cascades.Some of the coinhibitory members of this family, such as PD-1 and CTLA-4, already constitute approved targets in cancer therapy and, since 2011, have opened a new area of antitumour immunotherapy.Many antibodies targeting other inhibitory receptors (Tim-3, VISTA, Lag-3 and so on) or activating costimulatory molecules (OX40, GITR and so on) are under evaluation.These antibodies have multiple mechanisms of action.At the cellular level, these antibodies restore the activation signalling pathway and reprogram T cell metabolism.Tumour cells become resistant to apoptosis when an intracellular PD-L1 signalling is blocked.CD8 + T cells are considered to be the main effectors of the blockade of inhibitory receptors.Certain CD8 + T cell subsets, such as non-hyperexhausted (CD28 + , T-bet high , PD-1 int ), follicular-like (CXCR-5 + ) or resident memory CD8 + T cells, are more prone to be reactivated by anti-PD-1/PD-L1 monoclonal antibody (mAb).In the future, the challenge will be to rationally combine drugs able to make the tumour microenvironment more permissive to immunotherapy in order to potentiate its clinical activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2017-000213

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 84 references

Cited by

See all 324

Metadata

Authors
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E.
Venue
ESMO Open
Publisher
Elsevier BV
Published
2017
Volume
2
Issue
2
Pages
e000213
ISSN
2059-7029 (ISSN-L)
OpenAlex
W2724136428
Cited by
324
References
84
FWCI
12.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. https://app.cochat.ai/papers/10.1136/esmoopen-2017-000213
The paper
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017). Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2017-000213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.